Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEADER: Ribociclib in Combination With Adjuvant Endocrine Therapy for ER-positive Breast Cancer
NCT03285412Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2017
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ribociclib in breast cancer, sponsored by Massachusetts General Hospital. Started Dec 2017; status: active, not recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03285412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03285412.